鼻咽癌免疫治疗研究热点的文献计量学分析  

Bibliometrics Analysis of Research Hotspots in Immunotherapy for Nasopharyngeal Carcinoma

作　　者：乔元 王莉[1] 曹少华[1] 谢栋[2] 冯谢敏[1] QIAO Yuan;WANG Li;CAO Shaohua;XIE Dong;FENG Xiemin(Yan′an University Affiliated Hospital,Yan′an,Shaanxi,China 716000;Tianjin Medical University General Hospital,Tianjin,China 300070)

机构地区：[1]延安大学附属医院,陕西延安716000 [2]天津医科大学总医院,天津300070

出　　处：《中国药业》2025年第1期37-42,共6页China Pharmaceuticals

基　　金：陕西省教育厅专项科研计划项目[21JK0990]。

摘　　要：目的为深入研究免疫检查点抑制剂用于治疗鼻咽癌提供参考。方法采用计算机检索Web of Science核心合集数据库中鼻咽癌免疫治疗的相关文献,检索时限为自建库起至2023年12月31日。对鼻咽癌免疫治疗相关研究的发文量、国家、机构、作者、发表期刊、关键词共现、共被引情况进行可视化分析。结果共纳入文献381篇,年发文量在2015年后整体呈快速上升趋势;发文量最多的国家为中国(224篇),其次为美国(69篇);发文量最多的机构和作者为中山大学(72篇)及其ZHANG Li;关键词聚为5类,聚类研究主题主要有免疫疗法、抗肿瘤活性、程序性细胞死亡配体1(PD-L1)、程序性细胞死亡受体1(PD-1)、有效性、安全性、EB病毒、Ⅰ/Ⅱ期临床试验、生物标记物等;共被引频次最高的文献为MA等发表纳武利尤单抗的国际多中心研究(127次)。结论靶点及作用机制、PD-1、有效性、安全性、临床试验、生物标记物等是当前鼻咽癌免疫治疗的研究热点。我国已有国产创新药PD-1抑制剂获批上市,且鼻咽癌患者样本基数大,建议开展多中心、大样本的临床研究。Objective To provide a reference for further research on the use of immune checkpoint inhibitors in the treatment of nasopharyngeal carcinoma.Methods The literature related to immunotherapy for nasopharyngeal carcinoma in the Web of Science core collection database was searched from the inception to December 31,2023.Visual analysis was performed on the publication volume,countries,institutions,authors,published journals,co-occurrence of keywords,and co-citation status of studies related to immunotherapy for nasopharyngeal carcinoma.Results A total of 381 studies were included,and the annual publication volume showed a rapid upward trend after 2015.The country with the highest number of publications was China(224 studies),followed by the United States of America(69 studies).The institution and author with the highest number of publications was Sun Yat-Sen University(72 articles)and ZHANG Li,respectively.The keywords were clustered into five categories,and the research topics mainly included immunotherapy,anti-tumor activity,programmed-cell death ligand 1(PD-L1),programmed-cell death receptor 1(PD-1),efficacy,safety,Epstein-barr virus,phaseⅠ/Ⅱclinical trials,biomarkers,etc.The most frequently co-cited reference was an international multicenter study of Nivolumab published by MA et al(127 times).Conclusion Drug targets and mechanisms of action,PD-1,efficacy,safety clinical trials,and biomarkers are the current research hotspots of immunotherapy for nasopharyngeal carcinoma.Domestic innovative drugs PD-1 inhibitors have already been approved,and the number of patients with nasopharyngeal carcinoma in China is large.It is recommended to conduct clinical studies based on multicenter and large sample sizes.

关 键 词：鼻咽癌 免疫治疗 文献计量学 免疫检查点抑制剂 研究热点 可视化分析 

分 类 号：R987[医药卫生—药品] R979.5[医药卫生—药学]